# OnCo record tp53-del17p (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/tp53-del17p/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "tp53-del17p" ;
  schema:name "TP53 mutation and del(17p)"@en ;
  schema:alternateName "TP53 mutation"@en, "TP53-mutated"@en, "del(17p)"@en, "17p deletion"@en, "17p-"@en, "TP53 aberration"@en, "p53 abnormal"@en, "TP53 disruption"@en, "TP53mut"@en ;
  schema:description "TP53 mutation, or deletion of the 17p arm that carries the gene, is the single most common change in cancer and carries a worse outlook almost everywhere. In chronic lymphocytic leukaemia it decides treatment: chemotherapy is avoided and venetoclax's first approval was for del(17p) disease."@en ;
  schema:url <https://onco.cc/biomarkers/tp53-del17p/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:tag "biomarker", "tp53" ;
  onco:related <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/idh1-r132/> ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-relapsed/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/endometrial-p53-abnormal/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/ovarian/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/> ;
  onco:terms <https://onco.cc/terms/tp53-mutated/>, <https://onco.cc/terms/del17p-tp53/>, <https://onco.cc/terms/li-fraumeni/>, <https://onco.cc/terms/fish/> .